Austin, Texas — According to state and local development sources, XBiotech plans to invest $30,000,000.00 to build out 97,400 square feet of new space in Austin. The company plans to occupy the new space at 5217 Winnebago Lane in Austin, on or about January 1, 2029. According to the company website XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

To learn more about XBiotech, visit http://www.xbiotech.com/

Company Contact:
John Simard, Chairman and Chief Executive Officer
jsimard@xbiotech.com
512-386-2900

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.